ME Stock Overview
23andMe Holding Co. operates as a consumer genetics testing company.
23andMe Holding Co. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.05|
|52 Week High||US$8.86|
|52 Week Low||US$2.12|
|1 Month Change||-2.87%|
|3 Month Change||-7.58%|
|1 Year Change||-59.55%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-68.88%|
Recent News & Updates
|ME||US Healthcare||US Market|
Return vs Industry: ME underperformed the US Healthcare industry which returned 9.7% over the past year.
Return vs Market: ME underperformed the US Market which returned -18.9% over the past year.
|ME Average Weekly Movement||10.4%|
|Healthcare Industry Average Movement||8.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: ME is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ME's weekly volatility (10%) has been stable over the past year.
About the Company
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.
23andMe Holding Co. Fundamentals Summary
|ME fundamental statistics|
Is ME overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ME income statement (TTM)|
|Cost of Revenue||US$159.54m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.69|
|Net Profit Margin||-105.68%|
How did ME perform over the long term?See historical performance and comparison